Presentation is loading. Please wait.

Presentation is loading. Please wait.

Nat. Rev. Neurol. doi: /nrneurol

Published byJohnathan Martin Modified over 6 years ago

Similar presentations

Presentation on theme: "Nat. Rev. Neurol. doi: /nrneurol"— Presentation transcript:

1 Nat. Rev. Neurol. doi:10.1038/nrneurol.2015.157
Figure 3 Subtraction MRI in a patient with relapsing–remitting multiple sclerosis Figure 3 | Subtraction MRI in a patient with relapsing–remitting multiple sclerosis. T2 fluid-attenuated inversion recovery (FLAIR) images a | at baseline and b | after 1 year. c | A subtraction of these two images highlights the new and enlarging lesions (arrows). Wattjes, M. P. et al. (2015) MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis—establishing disease prognosis and monitoring patients Nat. Rev. Neurol. doi: /nrneurol

Download ppt "Nat. Rev. Neurol. doi: /nrneurol"

Similar presentations

Table 3 Limb-girdle muscular dystrophy standardized data collection form and HPO mapping Thompson, R. & Straub, V. et al. (2016) Limb-girdle muscular dystrophies.

Table 3 Limb-girdle muscular dystrophy standardized data collection form and HPO mapping Thompson, R. & Straub, V. et al. (2016) Limb-girdle muscular dystrophies.
Neurology Resident and Fellow Section

Neurology Resident and Fellow Section
Nat. Rev. Neurol. doi:10/1038/nrneurol

Nat. Rev. Neurol. doi:10/1038/nrneurol
Figure 3 Life expectancy at birth in all countries included

Figure 3 Life expectancy at birth in all countries included
MRI and possible differentiating features with nonconventional MRI

MRI and possible differentiating features with nonconventional MRI
Figure 1 Perivenous distribution of multiple sclerosis lesions

Figure 1 Perivenous distribution of multiple sclerosis lesions
Figure 2. MRI features of patients with MS who had antibodies to myelin oligodendrocyte glycoprotein MRI features of patients with MS who had antibodies.

Figure 2. MRI features of patients with MS who had antibodies to myelin oligodendrocyte glycoprotein MRI features of patients with MS who had antibodies.
Figure 4 Paradoxical immune reconstitution inflammatory syndrome

Figure 4 Paradoxical immune reconstitution inflammatory syndrome
Figure 2 The US Centers for Disease Control and

Figure 2 The US Centers for Disease Control and
Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol
Figure 1 Carotid artery inflammation detected using 18F-FDG-PET

Figure 1 Carotid artery inflammation detected using 18F-FDG-PET
Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol
Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol
Figure 2 Overview of risk factors for Parkinson disease dementia

Figure 2 Overview of risk factors for Parkinson disease dementia
Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol
Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol
Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol
Figure 3 Brain MRI findings in patients with MOG-Ab Extensive brain lesions with large diameter (A and B), posterior reversible encephalopathy–like lesions.

Figure 3 Brain MRI findings in patients with MOG-Ab Extensive brain lesions with large diameter (A and B), posterior reversible encephalopathy–like lesions.
Figure 3 Proportion of patients for whom NEDA

Figure 3 Proportion of patients for whom NEDA
Figure 5 Number of AHSCT procedures for

Figure 5 Number of AHSCT procedures for

Similar presentations

Ads by Google